No Data
No Data
The index ETF of Growth 250 is continuing to battle against the 75-day moving average, and biotech-related stocks remain the focus of the market.
An emerging market is likely to see profit-taking sales against the current rebound, but expect a strong outlook against the backdrop of improving investor sentiment. The Growth Market 250 Index is testing the 75-day moving average breakthrough. On June 27th, it exceeded the 75-day moving average on a closing price basis for the first time since April 1st, but over the weekend, it fell below this level. With the 25-day moving average firmly upward, this week will see a further rise to 200.
Emerging markets outlook: Growth 250 index continues to battle with its 75-day moving average, while biotech remains the focus of buying interest.
The emerging markets have been showing a clear upward trend on a monthly basis in June. In contrast with the Nikkei average's +2.56%, the growth market index rose by +3.43%, and the growth market 250 index increased by +3.65%, making it a favorable situation for emerging markets. Bio stocks were generally bought, with Sanbio <4592> rising four consecutive limits, and large-cap stocks were also strong, so the growth market index has risen for six consecutive days until June 27, and the growth market 250 index...
RaQualia Pharma: Corrected Securities Report - 16th term (January 1, 2023 - December 31, 2023)
RaQualia Pharma: Financial results briefing materials for the 1st quarter of the fiscal year ending 2024/12
RaQualia Pharma: Confirmation letter
RaQualia Pharma: Quarterly Report - 17th Quarter 1st Quarter (2024/01/01 - 2024/03/31)
No Data